Institution
Lankenau Medical Center
Healthcare•Philadelphia, Pennsylvania, United States•
About: Lankenau Medical Center is a healthcare organization based out in Philadelphia, Pennsylvania, United States. It is known for research contribution in the topics: Atrial fibrillation & Warfarin. The organization has 436 authors who have published 414 publications receiving 7095 citations. The organization is also known as: Lankenau Hospital.
Papers
More filters
••
Lankenau Institute for Medical Research1, Lankenau Medical Center2, Mayo Clinic3, University of Padua4, Peking University5, Rutgers University6, Ege University7, Shiga University8, Oulu University Hospital9, Capital Medical University10, Okayama University11, University of Ulsan12, French Institute of Health and Medical Research13, Nippon Medical School14, Tel Aviv Sourasky Medical Center15, University of Amsterdam16
TL;DR: The J-wave syndromes (JWSs) consisting of the Brugada syndrome (BrS) and early repolarization syndrome (ERS) have captured the interest of the cardiology community over the past 2 decades following the identification of BrS as a new clinical entity.
419 citations
••
TL;DR: The efficacy of SGN-35, particularly in Hodgkin lymphoma, might be attributed to its effect on the tumor microenvironment, and diffusion of free MMAE from the targeted tumor cells could result in a bystander effect that kills the normal supporting cells in close proximity to the malignant cells.
Abstract: Brentuximab vedotin (SGN-35) is an antibody-drug conjugate (ADC) directed against the CD30 antigen expressed on Hodgkin lymphoma and anaplastic large cell lymphoma. SGN-35 consists of the cAC10 chimerized IgG1 monoclonal antibody SGN30, modified by the addition of a valine-citrulline dipeptide linker to permit attachment of the potent inhibitor of microtubule polymerization monomethylauristatin E (MMAE). In phase II trials, SGN-35 produced response rates of 75% in patients with Hodgkin lymphoma ( n = 102) and 87% in patients with anaplastic large cell lymphoma ( n = 30). Responses to SGN-35 might be related not only to the cytotoxic effect due to release of MMAE within the malignant cell but also to other effects. First, SGN-35 may signal malignant cells through CD30 ligation to deliver an apoptotic or proliferative response. The former would amplify the cytotoxicity of MMAE. A proliferative signal delivered in the context of MMAE intoxication could enhance cell death. Second, the efficacy of SGN-35, particularly in Hodgkin lymphoma, might be attributed to its effect on the tumor microenvironment. Diffusion of free MMAE from the targeted tumor cells could result in a bystander effect that kills the normal supporting cells in close proximity to the malignant cells. The elimination of T regulatory cells that inhibit cytotoxic effector cells and elimination of cells that provide growth factor support for Hodgkin/Reed–Sternberg cells could further enhance the cytotoxic activity of SGN-35. Here we review the biology of SGN-35 and the clinical effects of SGN-35 administration. Clin Cancer Res; 17(20); 6428–36. ©2011 AACR .
325 citations
••
01 Aug 2013
TL;DR: The reversal of established medical practice is common and occurs across all classes of medical practice, and sheds light on low-value practices and patterns of medical research.
Abstract: Objective: To identify medical practices that offer no net benefits. Methods: We reviewed all original articles published in 10 years (2001-2010) in one high-impact journal. Articles were classified on the basis of whether they addressed a medical practice, whether they tested a new or existing therapy, and whether results were positive or negative. Articles were then classified as 1 of 4 types: replacement, when a new practice surpasses standard of care; back to the drawing board, when a new practice is no better than current practice; reaffirmation, when an existing practice is found to be better than a lesser standard; and reversal, when an existing practice is found to be no better than a lesser therapy. This study was conducted from August 1, 2011, through October 31, 2012. Results: We reviewed 2044 original articles, 1344 of which concerned a medical practice. Of these, 981 articles (73.0%) examined a new medical practice, whereas 363 (27.0%) tested an established practice. A total of 947 studies (70.5%) had positive findings, whereas 397 (29.5%) reached a negative conclusion. A total of 756 articles addressing a medical practice constituted replacement, 165 were back to the drawing board, 146 were medical reversals, 138 were reaffirmations, and 139 were inconclusive. Of the 363 articles testing standard of care, 146 (40.2%) reversed that practice, whereas 138 (38.0%) reaffirmed it. Conclusion: The reversal of established medical practice is common and occurs across all classes of medical practice. This investigation sheds light on low-value practices and patterns of medical research.
318 citations
••
Lankenau Medical Center1, University of Cambridge2, University of California, Los Angeles3, Mission Health System4, Virginia Commonwealth University5, University of Washington6, University of Milan7, Georgetown University8, University of Maryland, Baltimore9, Heidelberg University10, Harvard University11, Columbia University12, Case Western Reserve University13, University of Cape Town14, Mayo Clinic15, Innsbruck Medical University16, University of Pennsylvania17, MetroHealth18, Ohio State University19, Northwestern University20, University of Lausanne21, University of Texas Southwestern Medical Center22, University of Miami23, Cleveland Clinic24, University of the Republic25, Maine Medical Center26, Baylor College of Medicine27, Université libre de Bruxelles28
TL;DR: International experts from neurosurgery, neurocritical care, neurology, critical care, neuroanesthesiology, nursing, pharmacy, and informatics undertook a systematic literature review to develop recommendations about specific topics on physiologic processes important to the care of patients with disorders that require neuro critical care.
Abstract: Neurocritical care depends, in part, on careful patient monitoring but as yet there are little data on what processes are the most important to monitor, how these should be monitored, and whether monitoring these processes is cost-effective and impacts outcome. At the same time, bioinformatics is a rapidly emerging field in critical care but as yet there is little agreement or standardization on what information is important and how it should be displayed and analyzed. The Neurocritical Care Society in collaboration with the European Society of Intensive Care Medicine, the Society for Critical Care Medicine, and the Latin America Brain Injury Consortium organized an international, multidisciplinary consensus conference to begin to address these needs. International experts from neurosurgery, neurocritical care, neurology, critical care, neuroanesthesiology, nursing, pharmacy, and informatics were recruited on the basis of their research, publication record, and expertise. They undertook a systematic literature review to develop recommendations about specific topics on physiologic processes important to the care of patients with disorders that require neurocritical care. This review does not make recommendations about treatment, imaging, and intraoperative monitoring. A multidisciplinary jury, selected for their expertise in clinical investigation and development of practice guidelines, guided this process. The GRADE system was used to develop recommendations based on literature review, discussion, integrating the literature with the participants' collective experience, and critical review by an impartial jury. Emphasis was placed on the principle that recommendations should be based on both data quality and on trade-offs and translation into clinical practice. Strong consideration was given to providing pragmatic guidance and recommendations for bedside neuromonitoring, even in the absence of high quality data.
295 citations
••
TL;DR: Patients who experienced major bleed on dabigatran required more red cell transfusions but received less plasma, required a shorter stay in intensive care, and had a trend to lower mortality compared with those who had major bleeding on warfarin.
Abstract: Background—The aim of this study was to compare the management and prognosis of major bleeding in patients treated with dabigatran or warfarin. Methods and Results—Two independent investigators reviewed bleeding reports from 1034 individuals with 1121 major bleeds enrolled in 5 phase III trials comparing dabigatran with warfarin in 27 419 patients treated for 6 to 36 months. Patients with major bleeds on dabigatran (n=627 of 16 755) were older, had lower creatinine clearance, and more frequently used aspirin or non-steroid anti-inflammatory agents than those on warfarin (n=407 of 10 002). The 30-day mortality after the first major bleed tended to be lower in the dabigatran group (9.1%) than in the warfarin group (13.0%; pooled odds ratio, 0.68; 95% confidence interval, 0.46–1.01; P=0.057). After adjustment for sex, age, weight, renal function, and concomitant antithrombotic therapy, the pooled odds ratio for 30-day mortality with dabigatran versus warfarin was 0.66 (95% confidence interval, 0.44–1.00; P=0...
258 citations
Authors
Showing all 440 results
Name | H-index | Papers | Citations |
---|---|---|---|
Abass Alavi | 113 | 1298 | 56672 |
Robert T. Sataloff | 51 | 680 | 10252 |
Flemming Forsberg | 49 | 333 | 9769 |
Michael D. Ezekowitz | 43 | 164 | 16799 |
Gan-Xin Yan | 42 | 105 | 10110 |
William A. Gray | 41 | 135 | 6830 |
Peter D. Le Roux | 36 | 81 | 4522 |
James M. Mullin | 35 | 98 | 4095 |
Georgia Panagopoulos | 32 | 102 | 3250 |
Karen Chiswell | 30 | 132 | 3477 |
Peter R. Kowey | 29 | 113 | 3083 |
Tracey L. Evans | 29 | 97 | 4465 |
Pietro Delise | 27 | 103 | 5080 |
Caleb B. Kallen | 24 | 44 | 3517 |
Louis E. Samuels | 23 | 95 | 2380 |